Chemotherapy and the war on cancer

Nature Reviews Cancer

Volumn 5, Issue 1, 2005, Pages 65-72

  Chabner, Bruce A ^a   Roberts Jr , Thomas G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMITOTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CARBOPLATIN; CETUXIMAB; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; FOLIC ACID ANTAGONIST; GEFITINIB; IMATINIB; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; NITROSOUREA; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; DRUG EFFICACY; HUMAN; KIDNEY INJURY; MONOTHERAPY; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TESTIS CANCER; TUMOR CELL LINE; HISTORY; NEOPLASM; UNITED STATES;

ANTINEOPLASTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS; UNITED STATES;

EID: 11144242211     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1529     Document Type: Review

References (91)

1. Papac, R. J. Origins of cancer therapy. Yale J. Biol. Med. 74, 391-398 (2001).
2. Gilman, A. The initial clinical trial of nitrogen mustard. Am. J. Surg. 105, 574-578 (1963).
3. Gilman, A. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 103, 409-436 (1946).
4. Wills, L., Clutterbuch, P. & Evans, B. D. F. A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. Biochem. J. 31, 2136-2147 (1937).
5. Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F. & Wolff, J. A. Temporary remissions in acute leukemia in children produced by folic antagonist, 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med. 238, 787-793 (1948).
6. Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405-410 (1976).
7. Li, M. C., Hertz, R. & Bergenstal, D. M. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N. Engl. J. Med. 259, 66-74 (1958).
8. Jaffe, N., Frei, E. 3rd, Traggis, D. & Bishop, Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N. Engl. J. Med. 291, 994-997 (1974).
9. Jaffe, N. et al. High-dose methotrexate in osteogenic sarcoma. Natl Cancer Inst. Monogr. 56, 201-206 (1981).
10. Osbom, M. J., Freeman, M. & Huennekens, F M. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc. Soc. Exp. Biol. Med. 97, 429-431 (1958).
11. Osborn, M. J. & Huennekens, F. M. Enzymatic reduction of dihydrofolic acid. J. Biol. Chem. 233, 969-974 (1958).
12. Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J. & Chabner, B. A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309, 1094-104 (1983).
13. Messmann, R. A. & Allegra, C. J. In Cancer Chemotherapy and Biotherapy (eds Chabner, B. A. & Longo, D.) 139-184 (Lippincott Williams &Wilkins, Philadelphia, 2001).
14. Curt, G. A., Clendeninn, N. J. & Chabner, B. A. Drug resistance in cancer. Cancer Treat. Rep. 68, 87-99 (1984).
15. Stoller, R. G., Hande, K. R., Jacobs, S. A., Rosenberg, S. A. & Chabner, B. A. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N. Engl. J. Med. 297, 630-634 (1977).
16. Skipper, H. E., Thomson, J. R., Elion, G. B. & Hitchings, G. H. Observations on the anticancer activity of 6-mercaptopurine. Cancer Res. 14, 294-298 (1954).
17. Hitchings, G. H. & Elion, G. B. The chemistry and biochemistry of purine analogs. Ann. NY Acad. Sci. 60, 195-199 (1954).
18. Johnson, I. S., Armstrong, J. G., Gorman, M. & Burnett, J. P. Jr. The Vinca alkaloids: a new class of oncolytic agents. Cancer Res. 23, 1390-1427 (1963).
19. Bensch, K. G. & Malawista, S. E. Microtubule crystals: a new biophysical phenomenon induced by Vinca alkaloids. Nature 218, 1176-1177 (1968).
20. Frei, E. 3rd et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26, 642-656 (1965).
21. Frei, E. 3rd. The National Cancer Chemotherapy Program. Science 217, 600-606 (1982).
22. Driscoll, J. S. The preclinical new drug research program of the National Cancer Institute. Cancer Treat. Rep. 68, 63-76 (1984).
23. Grever, M. R., Schepartz, S. A. & Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19, 622-638 (1992).
24. Skipper, H. E., Schabel, F. M. Jr. & Wilcox, W. S. Experimental evaluation of potential anticancer agents. Xiii. On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chemother. Rep. 35, 1-111 (1964).
25. Skipper, H. E. & Griswold, D. P. Frank M. Schabel 1918-1983. Cancer Res. 44, 871-872 (1984).
26. Moxley, J. H. 3rd, De Vita, V. T., Brace, K. & Frei, E. 3rd. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res. 27, 1258-1263 (1967).
27. Devita, V. T. Jr., Serpick. A. A. & Carbone, P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 73, 881-695 (1970).
28. Levitt, M. et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 29, 630-636 (1972).
29. Berd, D., Comog, J., DeConti, R. C., Levitt, M. & Bertino, J. R. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 35, 1050-1054 (1975).
30. Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352-358 (1990).
31. McGuire, W. P. et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111, 273-279 (1989).
32. Goodman, J. & Walsh, V. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-cancer Drug (Cambridge Univ., Cambridge, 2001).
33. Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
34. Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85-91 (2002).
35. Bodurka, D. C. et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 21, 291-297 (2003).
36. Von Hoff, D. D. There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4, 1079-1086 (1998).
37. Johnson, J. I. et al. Relationships between drug activity in NCl preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
38. Rosenberg, B., Vancamp, L. & Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699 (1965).
39. Bosl, G. J. et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J. Clin. Oncol. 4, 1493-1499 (1986).
40. Evans, B. D., Raju, K. S., Calvert, A. H., Hartand, S. J. & Wiltshaw, E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat. Rep. 67, 997-1000 (1983).
41. Montgomery, J. A. Chemistry and structure-activity studies of the nitrosoureas. Cancer Treat. Rep. 60, 651-664 (1976).
42. Walker, M. D. & Hurwitz, B. S. BCNU (1,3-biS(2-chloroethyl)-1- nitrosourea; NSC-409962) in the treatment of malignant brain tumor - a preliminary report. Cancer Chemother. Rep. 54, 263-271 (1970).
43. Wilson, C. B., Boldrey, E. B. & Enot, K. J. 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother. Rep. 54, 273-281 (1970).
44. Rai, K. R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
45. Minocha, A. & Long, B. H. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Biochem. Biophys. Res. Commun. 122, 165-170 (1984).
46. Freireich, E. J., Schmidt, P. J., Schneiderman, M. A. & Frei, E. 3rd. A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N. Engl. J. Med. 260, 6-11 (1959).
47. Gaydos, L. A., Freireich, E. J. & Mantel, N. The quantitative relation between platelet count and hemorrhage in patients with acute leukema. N. Engl. J. Med. 266, 905-909 (1962).
48. Pizzo, P. A. Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 54, 2649-2661 (1984).
49. Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N. Engl. J. Med. 327, 28-35 (1992).
50. Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N. Engl. J. Med. 327, 99-106 (1992).
51. Curtis, R. E. et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326, 1745-1751 (1992).
52. Burstein, H. J. & Winer, E. P. Primary care for survivors of breast cancer. N. Engl. J. Med. 343, 1086-1094 (2000).
53. Johnson, J., Monks, A., Hollingshead, M. & Sausville, E. in Cancer Chemotherapy and Biotherapy (eds Chabner, B. A. & Longo, D.) 17-36 (Lippincott Williams & Wilkins, Philadelphia, 2001).
54. Whitesell, L., Mimnaugh, E. G., DeCosta, B., Myers, C. E. & Neckers, L. M. Inhibition of heat shock protein HSP90-pp60V-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad. Sci. USA 91, 8324-8328 (1994).
55. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol. 46, 1831-1840 (1993).
56. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983).
57. Paull, K. D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algortthm. J. Natl Cancer Inst. 81, 1088-1092 (1989).
58. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
59. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
60. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
61. Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
62. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer potyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
63. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
64. Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).
65. Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
66. Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
67. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
68. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
69. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
70. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
71. Roberts, T. G. Jr. & Chabner, B. A. Beyond fast track for drug approvals. N. Engl. J. Med. 351, 501-505 (2004).
72. Adjei, A. A. et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 1760-1766 (2003).
73. Sharma, S. et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracll and irinotecan. Ann. Oncol. 13, 1067-1071 (2002).
74. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
75. Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85-90 (1994).
76. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
77. Roninson, I. B. et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl Acad. Sci. USA 83, 4538-4542 (1986).
78. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
79. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
80. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941-2953 (1999).
81. Zubrod, C. G. The national program for cancer chemotherapy. JAMA 222, 1161-1162 (1972).
82. Takimoto, C. H. Anticancer drug development at the US National Cancer Institute. Cancer Chemother. Pharmacol. 52 (Suppl. 1), 29-33 (2003).
83. Kelland, L. R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40, 827-836 (2004).
84. Boyd, M. R. in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (ed. Teicher, B.) 23 (Humana, Totowa, 1997).
85. S. G. Cowen & Company. Pharmaceutical Therapeutic Categories Outlook: Comprehensive Study 375 (S.G. Cowen & Company, New York, 2004).
86. Schrag, D. The price tag on progress - chemotherapy for colorectal cancer. N. Engl. J. Med. 351, 317-319 (2004).
87. Ernst & Young LLP, Annual Biotechnology Industry Report, 2001. In Parexel's Pharmaceutical R&D Statistical Sourcebook (Parexel, Walthan, 2002/2003).
88. Pharmaceuticals Research and Manufacturers of America. New Medicines in Development for Cancer: 395 New Medicines in Development Offer Hope in the War on Cancer 1-56 (PhRMA, Washington, 2003).
89. IMS LifeCycle, R&D focus. In Parexel's Pharmaceutical R&D Statistical Sourcebook (Parexel, Walthan, 2003/2004).
90. Chabner, B. The traveling oncologist and the wages of sin. Oncologist 6, 1-2 (2001).
91. Gorlick, R. et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. New Engl. J. Med. 335, 1041-1048 (1996).